Ascend
PrivateLast Round
Strategic
Nov 12, 2024
Total Funding Raised
$263.5M
Company Overview
Ascend Gene And Cell Therapies is a biotechnology company specializing in the design, development, and manufacturing of cell therapies while promoting professional growth and scalable manufacturing practices within biotechnology teams.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ascend Comps
Public and private peers based on sector, stage, and business model.
Ascend Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Nov 12, 2024 | ||||
| Series A | Mar 20, 2023 | ||||
| Seed | Jun 22, 2021 |
Key People
Founding team and executive leadership
Ascend Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series A, Strategic |
| EW Healthcare Partners | Strategic |
| Digitalis Ventures | Series A, Strategic |
| DCVC Bio | Series A, Strategic |
| 4Bio Capital | Series A, Strategic |
| Ajinomoto Co., Inc. | Series A |
| Monograph Capital | Series A, Strategic, Seed |
Ascend Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ascend's valuation, stock price, and market status.
